Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription 09.02.2026 1 Am J Pathol 3 Ann Surg Oncol 7 Anticancer Res 3 BMC Cancer 1 Br J Cancer 7 Breast Cancer 5 Breast Cancer Res 11 Breast Cancer Res Treat 2 Breast J 1 Cancer 3 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 1 Cell 6 Clin Breast Cancer 2 Clin Cancer Res 1 Eur J Cancer 4 Eur J Surg Oncol 1 Eur Radiol 1 Gene 2 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 2 J Clin Invest 1 J Clin Oncol 1 JAMA 5 Lancet 1 Mod Pathol 1 Mol Ther Oncol 1 Nat Rev Clin Oncol 2 NPJ Breast Cancer 4 Oncol Rep 1 PLoS Comput Biol 1 PLoS Med 3 PLoS One 2 Proc Natl Acad Sci U S A 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. SAKAI A, Miyai Y, Shiraki Y, Ando R, et al
   Increased Meflin expression in cancer-associated fibroblasts restrains tumor cell proliferation and shapes vessel-rich stroma in triple-negative breast cancer.
   Am J Pathol. 2026 Feb 2:S0002-9440(26)00031-3. doi: 10.1016/j.ajpath.2026.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. FENTENER VAN VLISSINGEN EMALC, Postma EL, Scholten AN, van der Leij F, et al
   ASO Visual Abstract: The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate Our Former Strategy? Reevaluating the Role of Internal Mammary Sentinel Node Removal in B
   Ann Surg Oncol. 2026 Feb 5. doi: 10.1245/s10434-026-19159.
   PubMed        
   
   
3. RAYMAKERS AM, King TA, Mittendorf EA, Dey T, et al
   ASO Visual Abstract: Impact of Breast-Cancer-Related Lymphedema on Cancer Care Costs: Longitudinal and Age-Based Analyses.
   Ann Surg Oncol. 2026 Feb 3. doi: 10.1245/s10434-026-19141.
   PubMed        
   
   
4. TSUCHIDA J, Wu R, Nagahashi M, Ebos JML, et al
   ASO Visual Abstract: TRIM37 Expression is Associated with Immune Suppression, Poor Response to Neoadjuvant Chemotherapy, and Worse Survival in ER-Positive/HER2-Negative Breast Cancer.
   Ann Surg Oncol. 2026 Feb 2. doi: 10.1245/s10434-026-19108.
   PubMed        
   
   

   
   Anticancer Res

5. SHIRBACHE K, Shirbacheh K, Rezvani A, Shirbacheh A, et al
   Glucose Deprivation of Tumor Cells via Selective Nutrient Delivery: A Potential Therapy for Metastatic Breast Cancer.
   Anticancer Res. 2026;46:589-599.
   PubMed         Abstract available
   
   
6. TAKADA K, Kashiwagi S, Hirata M, Nishikawa M, et al
   Clinicopathological Significance of HER2 Expression Redefined by the HER2-low Concept in Ductal Carcinoma In Situ.
   Anticancer Res. 2026;46:901-909.
   PubMed         Abstract available
   
   
7. GAO S, Yu X, Li Y, Tao L, et al
   Radiotherapy Strategies for Stage II Breast Cancer With Lymphovascular Invasion After Mastectomy.
   Anticancer Res. 2026;46:1037-1052.
   PubMed         Abstract available
   
   
8. CHECK JH, Check DL, Ganpo-Nkewnkwa N
   Marked Palliative Benefits Seen With Treatment of Very Advanced Breast Cancer With the Progesterone Receptor Modulator Mifepristone.
   Anticancer Res. 2026;46:1153-1165.
   PubMed         Abstract available
   
   
9. DEMIRORS B, Ahmed SH, Grace K, Jimenez PB, et al
   Geographic Variations in Demographics, Socioeconomic Status, and Stage at Diagnosis Among Hormone Receptor-positive Invasive Ductal Carcinoma: An NCDB Analysis (2004-2020).
   Anticancer Res. 2026;46:811-817.
   PubMed         Abstract available
   
   
10. SASADA S, Takaya M, Suzuki K, Fujimoto M, et al
    Differences of HER2 Status by HercepTest and PATHWAY 4B5 Immunohistochemical Assays in Breast Cancer.
    Anticancer Res. 2026;46:1123-1130.
    PubMed         Abstract available
    
    
11. FUJIOKA S, Kashiwagi S, Kikukawa Y, Watanabe C, et al
    Prognostic Impact of Residual T and N Status After Neoadjuvant Therapy in Breast Cancer.
    Anticancer Res. 2026;46:939-947.
    PubMed         Abstract available
    
    

    
    BMC Cancer

12. TAO R, Liu B, Gao S, Zhang J, et al
    The role of CD26 in breast cancer and its pan-cancer analysis.
    BMC Cancer. 2026 Jan 30. doi: 10.1186/s12885-026-15656.
    PubMed         Abstract available
    
    
13. BRANDSTETTER LS, Grau A, Muller-Reiter M, Salmen J, et al
    Medication adherence in a German cohort of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study.
    BMC Cancer. 2026 Jan 30. doi: 10.1186/s12885-026-15641.
    PubMed        
    
    
14. CAMPONE M, Frenel JS, Kiver VII, Woeckel A, et al
    Treatment patterns and clinical outcomes in chemotherapy-treated patients with HR+/HER2- metastatic breast cancer using real-world data in France and Germany.
    BMC Cancer. 2026 Feb 3. doi: 10.1186/s12885-026-15611.
    PubMed        
    
    

    
    Br J Cancer

15. SHAABAN AE, Jourdain H, Desplas D, Vignot S, et al
    Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer.
    Br J Cancer. 2026 Feb 5. doi: 10.1038/s41416-026-03346.
    PubMed         Abstract available
    
    

    
    Breast Cancer

16. SATO R, Kamohara R, Matsuo T, Sawa A, et al
    Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial.
    Breast Cancer. 2026 Feb 5. doi: 10.1007/s12282-026-01828.
    PubMed        
    
    
17. PHAM YT, Wang R, Yuan JM, Luu HN, et al
    Low-carbohydrate diet score and risk of breast cancer: findings from a prospective cohort study.
    Breast Cancer. 2026 Feb 4. doi: 10.1007/s12282-026-01826.
    PubMed        
    
    
18. LI L, Wang M, Li X, Ding J, et al
    Exploring a specialized lactylation pattern to predict the prognosis and sensitivity of immunotherapy in breast cancer via machine learning.
    Breast Cancer. 2026 Feb 4. doi: 10.1007/s12282-026-01829.
    PubMed        
    
    
19. CHANG YK, Luk WP, Fung LH, Kwong A, et al
    Evaluating high-risk breast cancer surveillance outcomes in BRCA mutation carriers.
    Breast Cancer. 2026 Feb 3. doi: 10.1007/s12282-026-01822.
    PubMed        
    
    
20. PARK MS, Youn Y, Kim JA, Cho EH, et al
    Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.
    Breast Cancer. 2026 Jan 31. doi: 10.1007/s12282-025-01818.
    PubMed         Abstract available
    
    
21. TSURUTANI J, Noguchi K, Tanabe A
    Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan.
    Breast Cancer. 2026 Jan 31. doi: 10.1007/s12282-025-01814.
    PubMed        
    
    
22. SHIEN T, Ishitobi M, Sasaki K, Tanaka K, et al
    Efficacy and prognostic predictors of primary systemic therapy for de novo Stage IV breast cancer. Exploratory analysis of JCOG1017 PRIM-BC.
    Breast Cancer. 2026 Jan 31. doi: 10.1007/s12282-025-01821.
    PubMed        
    
    

    
    Breast Cancer Res

23. BASU GD, Innis PE, Deem AK, Starodynov A, et al
    Characterization of ESR1 alterations in patients with breast and gynecologic cancers.
    Breast Cancer Res. 2026;28:40.
    PubMed         Abstract available
    
    
24. SHEN S, Teysir J, Safonov A, Bromberg M, et al
    Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res. 2026 Jan 31. doi: 10.1186/s13058-025-02152.
    PubMed        
    
    
25. YANG L, Toriola AT
    Generational trends in reproductive factors among women in the US: implications for breast cancer incidence.
    Breast Cancer Res. 2026 Feb 3. doi: 10.1186/s13058-026-02222.
    PubMed         Abstract available
    
    
26. BURKE A, Fan S, Pfeiffer RM, Bodelon C, et al
    Associations of local breast density with patient characteristics and risk of breast cancer among women undergoing diagnostic breast biopsy.
    Breast Cancer Res. 2026 Feb 4. doi: 10.1186/s13058-025-02212.
    PubMed        
    
    
27. TENG X, Zhang J, Lai Q, Li W, et al
    Tumor heterogeneity index from DCE-MRI for AKT-inhibition responder identification and reveals hot immune microenvironment for patients with breast cancer: a multi-omics analysis of I-SPY2 trial.
    Breast Cancer Res. 2026;28:39.
    PubMed        
    
    

    
    Breast Cancer Res Treat

28. CHEN Y, Wang R, Wu L, Li J, et al
    Fertility preservation in breast cancer patients: a systematic review and summary of current evidence and recommendations.
    Breast Cancer Res Treat. 2026;215:68.
    PubMed         Abstract available
    
    
29. ROJAS DP, Frassoni S, Maisonneuve P, Intra M, et al
    A nomogram for predicting in-breast tumor recurrence risk in breast cancer patients treated with partial breast irradiation using intraoperative electron radiation therapy.
    Breast Cancer Res Treat. 2026;215:67.
    PubMed         Abstract available
    
    
30. CHUN S, Lee HR, Jung JH, Kim SH, et al
    Association of low muscle mass and obesity with mortality and cardiovascular outcomes in breast cancer: a population-based study.
    Breast Cancer Res Treat. 2026;215:70.
    PubMed         Abstract available
    
    
31. AMBURN T, Parvin-Nejad FP, Sevilimedu V, Zou H, et al
    Oncologic safety of prophylactic nipple-sparing mastectomy: Outcomes of 1,255 cases exceeding a 6-year median follow-up.
    Breast Cancer Res Treat. 2026;215:72.
    PubMed         Abstract available
    
    
32. JACQUINOT Q, Ennequin G, Falcoz A, Sawyer D, et al
    Exercise training decreases Neuregulin-1 concentrations in HER2-positive breast cancer patients undergoing adjuvant trastuzumab: the CARDAPAC study.
    Breast Cancer Res Treat. 2026;215:69.
    PubMed         Abstract available
    
    
33. REUL-HIRCHE HM, Dunn MR, Plinsinga ML, Laakso EL, et al
    The relationship between impaired upper-body function, quality of life and breast cancer-related lymphoedema: results from a prospective, population-based cohort study.
    Breast Cancer Res Treat. 2026;215:73.
    PubMed         Abstract available
    
    
34. TIELS LM, Walstra CJEF, Voogd AC, van der Sangen MJC, et al
    Postoperative complications after salvage mastectomy and repeat breast-conserving surgery in patients with IBTR after previous breast-conserving surgery: a multicenter, retrospective cohort study.
    Breast Cancer Res Treat. 2026;215:71.
    PubMed         Abstract available
    
    
35. GARG G, Bharath S, Krishna A, Sethi S, et al
    Diagnostic accuracy of tumor bed biopsy for predicting pathological complete response in breast cancer patients achieving clinical complete response after neoadjuvant chemotherapy: a meta-analysis.
    Breast Cancer Res Treat. 2026;215:75.
    PubMed         Abstract available
    
    
36. LEE TH, Lee H, Jang JY, Park W, et al
    Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion.
    Breast Cancer Res Treat. 2026;215:76.
    PubMed         Abstract available
    
    
37. LEBLANC A, Beltran-Bless AA, Pond GR, El Emam K, et al
    Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy.
    Breast Cancer Res Treat. 2026;215:74.
    PubMed         Abstract available
    
    
38. ZHANG Y, Peng J, Ma T, Liu X, et al
    TMEM205 promotes M2-like macrophage polarization and advances the progression of triple-negative breast cancer.
    Breast Cancer Res Treat. 2026;216:1.
    PubMed         Abstract available
    
    

    
    Breast J

39. SAGOE S, Clottey PT, Kwakye IN, Lamptey E, et al
    Adolescent Girls' Breast Self-Examination Practices in Eastern Region of Ghana.
    Breast J. 2026;2026:5207043.
    PubMed         Abstract available
    
    
40. REYES N, Ortega C, Mendiola A, Murray M, et al
    Identifying Disparities in Timely Receipt of Radiation After Breast-Conserving Surgery.
    Breast J. 2026;2026:9942451.
    PubMed         Abstract available
    
    

    
    Cancer

41. MA Y, Li X, Jiang Y, Xiao L, et al
    The safety of trastuzumab deruxtecan (T-DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta-analysis.
    Cancer. 2026;132:e70268.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

42. BISTA S, Harsanyi H, Khan M, Nambayan R, et al
    Breast cancer screening among cancer survivors: a systematic review and meta-analysis.
    Cancer Epidemiol Biomarkers Prev. 2026 Feb 6. doi: 10.1158/1055-9965.EPI-25-1465
    PubMed         Abstract available
    
    
43. VALDEZ D, Abe JV, Bohmann P, Bogumil D, et al
    Ethnic Mixture and Body Mass Index as Modifiers of Breast Cancer Risk Among Native Hawaiian Women: Insights from the Multiethnic Cohort.
    Cancer Epidemiol Biomarkers Prev. 2026 Feb 5. doi: 10.1158/1055-9965.EPI-25-1101
    PubMed         Abstract available
    
    
44. NYANTE SJ, Kajita Y, Tan X, Cohen EA, et al
    Association between Participant Characteristics and Breast Parenchymal Texture Variation among Postmenopausal Women.
    Cancer Epidemiol Biomarkers Prev. 2026;35:301-310.
    PubMed         Abstract available
    
    

    
    Cancer Res

45. BERENS EB, Khou S, Huang ET, Hoffman A, et al
    Neoplastic Immune Mimicry Potentiates Breast Tumor Progression.
    Cancer Res. 2026;86:587-603.
    PubMed         Abstract available
    
    

    
    Cell

46. ZHANG SW, Wang H, Xiao Y, Liu LT, et al
    Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment.
    Cell. 2026 Feb 5:S0092-8674(26)00048-6. doi: 10.1016/j.cell.2026.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

47. SARAH F, Jacienta P, Richard H, Lisa W, et al
    Triple Technique (Radioisotope, Blue Dye, and Embedded Fiducial Marker) for Identifying Sentinel Lymph Nodes Following Neoadjuvant Chemotherapy for Clinical Lymph Node Positive Breast Cancer; Is More Really Better?
    Clin Breast Cancer. 2026;26:87-92.
    PubMed         Abstract available
    
    
48. BISCHOFF H, Petit T
    CDK4/6 Inhibitors in HER2-positive Metastatic Breast Cancer.
    Clin Breast Cancer. 2026;26:93-104.
    PubMed         Abstract available
    
    
49. LI C, Zhang P, Wang J, Geng C, et al
    Omission of Axillary Lymph Node Dissection in Early-Stage Breast Cancer With Limited Sentinel Lymph Node Metastasis: A Propensity Score-Matched Analysis.
    Clin Breast Cancer. 2026 Jan 9:S1526-8209(25)00352.
    PubMed         Abstract available
    
    
50. LI Y, Li D, Tao X, Ye Y, et al
    Differences in Survival and Associated Characteristics Between Asian American and White Patients With Breast Cancer.
    Clin Breast Cancer. 2026;26:1-8.
    PubMed         Abstract available
    
    
51. ACCOMASSO F, Ruggeri G, Actis S, Paradiso E, et al
    Is Lobular Histology a Predictor of Sentinel Node Positivity in Early Breast Cancer? An Integrated Analysis of Histological Subtype and Preoperative Imaging.
    Clin Breast Cancer. 2026;26:9-16.
    PubMed         Abstract available
    
    
52. BROOKS JD, Blackmore KM, Ngo NNM, Walker MJ, et al
    Canadian Women's Attitudes Toward Receiving Personalized Breast Cancer Risk Information: Insights From the PERSPECTIVE I&I Project.
    Clin Breast Cancer. 2025 Dec 29:S1526-8209(25)00355.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

53. VOORTHUIS RAB, Oliveira M, van Rossum AGJ, de Boo LW, et al
    PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA results.
    Clin Cancer Res. 2026 Feb 3. doi: 10.1158/1078-0432.CCR-25-2833.
    PubMed         Abstract available
    
    
54. OLIVEIRA M, Ciruelos E, Villacampa G, Morales S, et al
    Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.
    Clin Cancer Res. 2026;32:468-478.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

55. NARDIN S, Bruzzone M, Arecco L, Chiappe E, et al
    Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies.
    Eur J Cancer. 2026;236:116266.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

56. EL-HALLAK H, Garvey LH, Tvedskov TF, Holmich LR, et al
    Perioperative hypersensitivity reactions to Patent Blue V in sentinel lymph node biopsy for breast cancer and melanoma.
    Eur J Surg Oncol. 2026;52:111459.
    PubMed         Abstract available
    
    
57. BARRANGER E, Najib B, Dejean C, Jacquinot F, et al
    Iodine(125) grain isotope detection compared to standard metal guide detection for breast cancers: The IODINE BREAST, a randomised, non-inferiority trial.
    Eur J Surg Oncol. 2026;52:111376.
    PubMed         Abstract available
    
    
58. KETLEY A, Martin C, Wyld L, King N, et al
    What makes a 'good' mastectomy? - A national qualitative study of health care professionals opinions on mastectomy without reconstruction.
    Eur J Surg Oncol. 2026;52:111333.
    PubMed         Abstract available
    
    
59. ZEHNPFENNIG L, Maggi N, Levy J, Loesch JM, et al
    Post-mastectomy radiotherapy negatively impacts short-term patient-reported outcomes in patients with and without immediate breast reconstruction - a retrospective cohort study.
    Eur J Surg Oncol. 2026;52:111305.
    PubMed         Abstract available
    
    

    
    Eur Radiol

60. LEHNEN T, Polenske D, Wichtmann BD, Lehnen NC, et al
    AI software as a third reader in breast cancer screening-a prospective diagnostic observational study.
    Eur Radiol. 2026 Feb 5. doi: 10.1007/s00330-026-12359.
    PubMed         Abstract available
    
    

    
    Gene

61. CUI R, Chen H, Zhao X, Xu S, et al
    PBX1-mediated transcription of AP1M2 promotes triple-negative breast cancer malignant progression and docetaxel resistance.
    Gene. 2026 Jan 30:150031. doi: 10.1016/j.gene.2026.150031.
    PubMed         Abstract available
    
    

    
    Int J Cancer

62. HAJIRAHIMKHAN A, Bartom ET, Chung CH, Guo X, et al
    Reprogramming SREBP1-dependent lipogenesis and inflammation in high-risk breast with licochalcone A: A novel path to cancer prevention.
    Int J Cancer. 2026;158:1927-1940.
    PubMed         Abstract available
    
    
63. ABUSANUGA M, Murtadi H, Kashbour M, Amer S, et al
    Enhancing breast cancer knowledge and clinical breast examination skills among healthcare providers at the polyclinics in Misrata, Libya.
    Int J Cancer. 2026 Feb 4. doi: 10.1002/ijc.70361.
    PubMed         Abstract available
    
    

    
    Int J Oncol

64. CHEN ZM, Huang P, Yang DY, Lin S, et al
    Advances in the study of the breast carcinoma exosomal microRNAs: From basic mechanisms to clinical applications (Review).
    Int J Oncol. 2026;68:38.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

65. 
    Erratum to: Wang C-C, McNamara AL, Shin J, Schuemann J, Grassberger C, Taghian AG, Jimenez RB, MacDonald SM, Paganetti H. End-of-range radiobiological effect on rib fractures in patients receiving proton therapy for breast cancer. Int J Radiat Oncol B
    Int J Radiat Oncol Biol Phys. 2026;124:884.
    PubMed        
    
    

    
    J Clin Invest

66. LI H, De Santis MC, Tucci FA, Tosoni D, et al
    SH3BP5L triggers the RAB11A-regulated integrin recycling network implicated in breast cancer metastasis.
    J Clin Invest. 2026;136:e192705.
    PubMed         Abstract available
    
    
67. KONG T, Ma CX
    Unraveling TIME: CD8+ T cell- and CXCL11-driven endocrine resistance in breast cancer.
    J Clin Invest. 2026;136:e200923.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

68. ROBERTSON JFR, Gogitidze T, Katashvili Z, Rocha JEB, et al
    Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.
    J Clin Oncol. 2026 Jan 16:JCO2501548. doi: 10.1200/JCO-25-01548.
    PubMed         Abstract available
    
    

    
    JAMA

69. PLEASANT V, Ring K
    What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors.
    JAMA. 2026 Feb 5. doi: 10.1001/jama.2026.0025.
    PubMed        
    
    

    
    Lancet

70. MARINOVICH ML, Houssami N
    AI for enhancing efficiency and effectiveness of population breast cancer screening.
    Lancet. 2026;407:471-473.
    PubMed        
    
    
71. KRISHNAN A, Mukherjee D
    Extended aromatase inhibitor therapy for early breast cancer.
    Lancet. 2026;407:494-495.
    PubMed        
    
    
72. BRAYBROOKE J, Bradley R, Hills R
    Extended aromatase inhibitor therapy for early breast cancer - Authors' reply.
    Lancet. 2026;407:495-496.
    PubMed        
    
    
73. SUSUMAN AS, Ramangoele T, Petros L, Dhludhlu K, et al
    Extended aromatase inhibitor therapy for early breast cancer.
    Lancet. 2026;407:495.
    PubMed        
    
    
74. GOMMERS J, Hernstrom V, Josefsson V, Sartor H, et al
    Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy tria
    Lancet. 2026;407:505-514.
    PubMed         Abstract available
    
    

    
    Mod Pathol

75. HU J, Tsang JY, Liu J, Hu H, et al
    Predictors of Response to Neoadjuvant Therapy in HER2-positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity.
    Mod Pathol. 2026 Jan 29:100935. doi: 10.1016/j.modpat.2025.100935.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

76. KOROTKAJA K, Rudevica Z, Lapina D, Skrastina D, et al
    Virus-based IFNgamma gene delivery and photodynamic therapy cooperate to remodel the tumor microenvironment and suppress breast cancer.
    Mol Ther Oncol. 2026;34:201124.
    PubMed         Abstract available
    
    

    
    Nat Rev Clin Oncol

77. LOBO-MARTINS S, Luen SJ, Piccart M, Loi S, et al
    Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.
    Nat Rev Clin Oncol. 2026 Feb 3. doi: 10.1038/s41571-026-01120.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

78. YILMAZ A, Haerri L, Granda ME, Coquoz O, et al
    The CXCL10/CXCR3 axis is essential for sustaining immunological dormancy in triple-negative breast cancer.
    NPJ Breast Cancer. 2026 Jan 30. doi: 10.1038/s41523-026-00903.
    PubMed         Abstract available
    
    
79. BAI K, Sung HJ, Chung YR, Shin HC, et al
    Impact of estrogen receptor expression levels on chemo-responsiveness and prognosis of breast cancer patients treated with neoadjuvant chemotherapy.
    NPJ Breast Cancer. 2026 Feb 4. doi: 10.1038/s41523-026-00907.
    PubMed         Abstract available
    
    

    
    Oncol Rep

80. CHEN Y, Wei L, Zhang X, Liu X, et al
    [Corrigendum] 3?Bromopyruvate sensitizes human breast cancer cells to TRAIL?induced apoptosis via the phosphorylated AMPK?mediated upregulation of DR5.
    Oncol Rep. 2026;55:56.
    PubMed         Abstract available
    
    
81. KOBAYASHI M, Konno C, Shimizu A, Kobayashi M, et al
    Tumor?associated glucocorticoid inhibition by mifepristone reduces polymorphonuclear myeloid?derived suppressor cells and promotes antitumor immunity in triple?negative breast cancer?bearing mice.
    Oncol Rep. 2026;55:60.
    PubMed         Abstract available
    
    
82. JIN Y, Zhang W, Wang H, Zhang Z, et al
    [Retracted] EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P?gp substrates in vitro and in vivo.
    Oncol Rep. 2026;55:61.
    PubMed         Abstract available
    
    
83. FU W, Lin L, Li J, Qin F, et al
    Quercetin reduces expression of ATP?binding cassette transporters by regulating the PTEN/PI3K/AKT signaling pathway in breast cancer cells.
    Oncol Rep. 2026;55:63.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

84. JI T, Yang B, Wang M, Ji H, et al
    AugGCL: Multimodal graph learning for spatial transcriptomics analysis with enhanced gene and morphological data.
    PLoS Comput Biol. 2026;22:e1013912.
    PubMed         Abstract available
    
    

    
    PLoS Med

85. NOTINI G, Bianchini G, Perez-Garcia JM, Cortes J, et al
    Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy.
    PLoS Med. 2026;23:e1004930.
    PubMed         Abstract available
    
    

    
    PLoS One

86. CAZAGRANDA IC, de Almeida RF, Smaniotto LL, de Andrade Berny MP, et al
    Hidden risks associated with occupational pesticide exposure in women with breast cancer: High frequency of the Luminal B molecular subtype and occurrence of poor prognostic features.
    PLoS One. 2026;21:e0339471.
    PubMed         Abstract available
    
    
87. MOHAMMAD HUSSIN N, Nik Jaafar NR, Idris IB, Mohammed Nawi A, et al
    Mental health help-seeking among individuals with breast cancer: A qualitative exploration of women's and healthcare practitioners' perspectives.
    PLoS One. 2026;21:e0342002.
    PubMed         Abstract available
    
    
88. STINTON S, Edwick D, Maxwell-Smith C, Bear N, et al
    Evaluating the effect of the SMART intervention in people with recently diagnosed breast cancer who are being treated at a public tertiary hospital in Australia: protocol and statistical analysis plan for a single-blinded, single centre randomised con
    PLoS One. 2026;21:e0341423.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

89. SERRA M, Rediti M, Collet L, Lifrange F, et al
    Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinoma.
    Proc Natl Acad Sci U S A. 2026;123:e2517567123.
    PubMed         Abstract available
    
    
90. ROJAS-JIMENEZ E, Bui TM, Yan P, Li Z, et al
    Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2501052123.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

91. MACHIELS M, Kaidar-Person O, Marta GN, Meattini I, et al
    Reconsidering the role of PMRT in low to intermediate risk breast cancer: Applying results from previous standards of treatment in the current multimodal practice.
    Radiother Oncol. 2026;217:111416.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum